Erlotinib works as an anti-tumor and is mainly used to treat locally advanced or metastatic non-small cell lung cancer that is positive for EGFR driver mutations, or to treat patients with advanced non-small cell lung cancer that has progressed after first-line chemotherapy, or progressed after second-line chemotherapy. Side effects include rash, diarrhea, and hepatic impairment.
1. Erlotinib is a first-generation targeted drug used to treat advanced non-small cell lung cancer. For advanced non-small cell lung cancer patients, if the patients have EGFR19 or EGFR21 gene mutation, they can choose erlotinib for treatment, which is more effective than chemotherapy and has less side effects.
2. For patients with advanced stage, if the disease progresses after first-line chemotherapy, erlotinib can be used in the second line. If the patient’s condition continues to progress after first- and second-line chemotherapy has been used, Erlotinib can be used as a third-line drug.
3. As an anti-tumor drug, common side effects of Erlotinib include skin side effects such as rash and itching, gastrointestinal side effects such as diarrhea and nausea, and hepatic side effects such as high transaminases.
4. It is contraindicated for those who are allergic to this product and its ingredients.
Note that professional medical guidance is required for the use of the drug.